Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

A diagnostics company that earlier this month had signaled plans to go public is taking a detour to the exit doors by agreeing to be acquired. San Francisco-based genetics company Invitae will put up ...

Invitae is boosting its neurology and cardiology diagnostic test offerings. The San Francisco-based company will be adding 11 panels for heritable diseases and will update 17 existing neurology panels ...

Invitae ($NVTA) is teaming up with personal genomics outfit Helix to make genetic testing apps for health and wellness. The apps, which combine Helix’s DNA ...

Shares of genetic testing leader Invitae (NYSE: NVTA) sank as much as 19.6% this morning after the company announced the pricing of a major stock offering. It may seem like Groundhog Day for investors ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

NEW YORK, Feb 15 (Reuters) - Invitae Corp received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a buyer and exit from Chapter 11 ...

The company is unprofitable and spent more than $100 million last quarter. Retail investors appear to be driving up shares of the company. Invitae may have become the latest meme stock. But Invitae ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...